Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthma
Knopp Biosciences LLC and the University of Leicester today announced timelines, trial details, and eligibility criteria for a planned Phase 2 clinical trial evaluating the oral eosinophil-lowering drug candidate dexpramipexole in severe eosinophilic asthma patients that is on track to begin in the first half of 2020.
The 52-week, randomized, double-blind, placebo-controlled trial will evaluate whether dexpramipexole is associated with a reduction in asthma exacerbations. Fifteen severe asthma centers across the United Kingdom (UK) will be enrolling up to 100 total participants in the trial, led by the Leicester Clinical Trials Unit of the University of Leicester.
“We are pleased to collaborate with world-renowned asthma investigators in the UK to assess the effects of oral dexpramipexole on asthma exacerbations,” said Michael Bozik, M.D., president and CEO of Knopp. “An unmet need remains for an orally administered medicine for eosinophilic asthma, and we welcome the opportunity to assess dexpramipexole as an alternative to injectable biologic treatments.”
Salman Siddiqui, M.D., Ph.D., Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester’s Hospitals, will serve as the Chief Investigator for the study. The clinical program is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK, with the drug candidate, matching placebo, and additional support provided by Knopp Biosciences.
The primary outcome measure is the annual rate of asthma exacerbations. Secondary outcomes include changes from baseline in Asthma Control Score (ACQ-6), lung function (FEV1), fractional exhaled nitric oxide (FeNO) levels, and a number of quality-of-life-related measures. Eligibility criteria include a history of exacerbation-prone asthma and elevated blood eosinophils (≥0.30 x109/L cells). Patients who have failed monoclonal antibody therapy are eligible to participate in the trial after a period of biologic washout (5 months).
Dexpramipexole is an orally available small molecule drug candidate shown to selectively reduce eosinophil levels in multiple clinical trials, including in a Phase 2 study in hypereosinophilic syndrome (HES) and a Phase 2 trial in chronic rhinosinusitis with nasal polyps. Knopp has separately initiated a Phase 2 dose-ranging biomarker trial in the United States of oral dexpramipexole in moderate-to-severe eosinophilic asthma. Eosinophils are white-blood cells that play a central role in several debilitating conditions, including asthma, HES, and other inflammatory diseases.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. In addition to developing oral dexpramipexole for eosinophil-associated diseases, Knopp directs its preclinical Kv7 platform to small molecule treatments for KCNQ2 epileptic encephalopathy and other CNS hyperexcitability disorders. Please visit www.knoppbio.com.
ABOUT THE UNIVERSITY OF LEICESTER
The University of Leicester is led by discovery and innovation – an international centre for excellence renowned for research, teaching and broadening access to higher education. It is among the top 25 universities in the Times Higher Education REF Research Power rankings with 75% of research adjudged to be internationally excellent with wide-ranging impacts on society, health, culture, and the environment. The University is home to just over 20,000 students and approximately 3,000 staff. Find out more at https://le.ac.uk/about.
MRC AND NIHR
The study was funded by an MRC and NIHR partnership created to support the evaluation of interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care.
1. The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR commissions applied health research to benefit the poorest people in low- and middle-income countries, using Official Development Assistance funding.
2. The Medical Research Council (MRC) is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers’ money in some of the best medical research in the world across every area of health. Thirty-three MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms. The Medical Research Council is part of UK Research and Innovation. https://mrc.ukri.org/
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Jefferies' Clients, Employees and Shareholders Contribute $4,000,000 AUD for Australia Wildfires Relief Efforts23.1.2020 03:07:00 EET | Press release
Jefferies announced today a total donation of $4.0 million AUD to organizations providing needed assistance to victims of the wildfires in Australia. The firm's clients helped to generate $1.6 million AUD in donations through Asia Pacific trading commissions on January 22nd. Voluntary donations from Jefferies’ 3,813 employees totaled $400,000 AUD and Jefferies as a firm matched these client and employee donations with an additional $2.0 million AUD. “We are proud of the entire Jefferies family and in particular, our newly expanded Pan Asian Team, for raising $4,000,000 AUD for relief efforts in Australia following the devastating wildfires,” commented Rich Handler, CEO of Jefferies, and Brian Friedman, President. “We greatly appreciate our clients globally, who directed their trading business to Jefferies as well as the voluntary donations from our employees. We are honored to assist in the recovery, and our hearts go out to those affected by these wildfires. We also thank all the dedi
AskNicely Opens Amsterdam Office To Meet Growing Demand in Europe22.1.2020 23:05:00 EET | Press release
AskNicely, the customer experience platform for people-powered businesses, today announced the opening of its first European office in Amsterdam. The company is headquartered in Portland, Oregon and recently expanded its original office in Auckland, New Zealand. “Amsterdam has become a hub for innovation,” said AskNicely co-founder and CEO Aaron Ward. “We recognize the potential of the city’s incredible talent pool, its world-class infrastructure, and the vibrant growth that has fueled the Amsterdam tech scene.” The European office was added in response to customer demand, and to accelerate the company’s growth plans. In 2019, AskNicely raised $10 million in Series A funding and expanded on its core NPS software by launching the world’s first mobile customer experience coaching app, which helps companies consistently deliver on their brand promise by using real-time feedback to coach employees. “I am delighted that AskNicely has chosen to set up its operations in the Netherlands and ho
Strong Revenue Growth in 2019 and Promising Outlook22.1.2020 19:45:00 EET | Press release
Kalray (Paris:ALKAL) (Euronext Growth Paris : ALKAL), a pioneer in processors for new intelligent systems, reviews its business in the second half of 2019 (from July 1 to December 31, 2019) and looks back over the highlights of the period. Eric Baissus, President of Kalray’s Executive Board, commented as follows: “2019 was a pivotal year for Kalray marked by the achievement of a number of key milestones. First of all, we finished developing our 3rd generation Coolidge™ processor and presented it for the first time in early January at CES. Mass production is scheduled to start second semester of 2020. Furthermore, strategic agreements were signed with top-tier players including NXP, Wistron, 2CRSI and Intron Technology, which will boost our credibility and accelerate time to market for Coolidge™. Our target of achieving revenues of €100 million by 2022 have been confirmed by the initial performances of Coolidge™, the industry enthusiasm which we were able to measure at CES and the numer
PMI Salary Survey Reveals Project Management Practitioners with the PMP Certification Earn 22% More22.1.2020 19:30:00 EET | Press release
The Project Management Institute (PMI) today released its “Earning Power: Project Management Salary Survey” which reveals a significant advantage in earning potential for practitioners who hold the Project Management Professional (PMP)® certification. According to the survey, respondents with a PMP certification reported higher median salaries than those without a PMP certification -- 22% higher on average across the 42 countries surveyed. New in this edition is salary information from five countries not previously covered— Indonesia, Pakistan, the Philippines, Portugal and the Russian Federation. The 11th edition of the survey incorporates information from more than 32,000 project management practitioners in 42 countries across the globe. The comprehensive biennial survey offers insight into the value of project management skills, experience and certifications. It is an industry-leading source of data, giving project management practitioners a greater awareness of their earning potent
Philip Morris International Wins 2020 BIG Innovation Award22.1.2020 18:05:00 EET | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that it has won the 2020 BIG Innovation Award in the “Organization” category. The company was honored for placing innovation front and center as it continues its full-scale business transformation to deliver a smoke-free future and replace cigarettes with better alternatives for those adults who would otherwise continue to smoke. The BIG Innovation Awards, presented by the Business Intelligence Group, recognize organizations, products and people who bring new ideas to life. Organizations from across the globe submitted their recent innovations for consideration, and nominations were judged by a select group of business leaders and executives. “It is gratifying to continue to be recognized by the broader business community for the innovation that is fueling our progress toward a smoke-free future,” said Jacek Olczak, PMI’s chief operating officer. “As we are undergoing the largest transformation in our company’s history,
Sevan Refreshes 14,000th Restaurant22.1.2020 17:00:00 EET | Press release
Sevan Multi-Site Solutions, Inc. (Sevan)—a global leader in innovative design, program management, construction services and data analytics—just finished refreshing their 14,000th restaurant. For eight years, Sevan has provided solutions for the world’s largest brands while accelerating development programs across the United States and Canada for multi-site clients. Sevan has partnered on restaurant programs with Carl’s Jr., Carrols Corporation (a Burger King franchisee), Chipotle, McDonald’s, Panera, Starbucks, Taco Bell, Army & Air Force Exchange Service (Exchange) restaurants and others. Sevan’s Chief Revenue Officer Jim Furis says working with great clients is the best part of the company’s success in the Quick Service Restaurant (QSR) world. “Each client is unique and their project execution style varies widely. Not surprisingly, they all share one objective—to deliver a fantastic customer experience in a reliable way at loads of locations,” Furis said. “Sevan is proud to have pla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom